Inspire Medical Systems reports Q3 2026 earnings beat and raises full‑year EPS guidance
Inspire Medical Systems posted Q3 2026 revenue of $206.7 million, topping estimates by about 1%. Adjusted earnings were $0.14 per share, beating consensus forecasts by $0.05. The company reaffirmed its FY 2026 revenue outlook of $850‑$860 million and lifted adjusted EPS guidance to $1.30, a 4% increase. Management highlighted a new Category I CPT code for the Inspire V device and ongoing investments to improve patient flow.
Why it matters
The earnings beat and higher EPS guidance suggest stronger profitability than analysts expected, which may support a higher valuation for INSP. The new CPT code and coding updates could ease reimbursement pressures, potentially boosting future sales.
Key facts
- 1Q3 2026 revenue was $206.7 million, exceeding estimates by 1.1%. finance.yahoo.com
- 2Adjusted EPS for Q3 2026 was $0.14, beating estimates by $0.05. investing.com
- 3Full‑year 2026 revenue guidance remains $850‑$860 million. investing.com
- 4Adjusted FY 2026 EPS guidance was raised to $1.30, a 4% increase. finance.yahoo.com
- 5Operating margin declined to -13.9% year‑on‑year. finance.yahoo.com
- 6Management cited a new Category I CPT code for Inspire V effective Jan 1 2028. finance.yahoo.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.